Presage Biosciences Adds Board Member
The oncology company Presage Biosciences has appointed David Johnson to its board of directors. With 25 years’ experience Johnson joins Presage from the oncology focused company, Acerta Pharma, where he was CEO. He has held roles with increasing responsibilities within clinical development, medical affairs, pipeline development, and commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche.
You may also be interested in...
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
Board directors appointed at Athersys, Trillium Therapeutics and Viatris
Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead
CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.